6-Morpholinonicotinic Acid → HCID 178523598, Verbindung
Reaktionsgleichung
Cl.Cl.[O:3]1[C:7]2[CH:8]=[CH:9][CH:10]=[C:11]([CH:12]3[CH2:17][CH2:16][N:15]([CH2:18][CH2:19][C@H:20]4[CH2:25][CH2:24][C@H:23]([NH2:26])[CH2:22][CH2:21]4)[CH2:14][CH2:13]3)[C:6]=2[CH2:5][CH2:4]1.[N:27]1([C:33]2[CH:41]=[CH:40][C:36]([C:37](O)=[O:38])=[CH:35][N:34]=2)[CH2:32][CH2:31][O:30][CH2:29][CH2:28]1>>[O:3]1[C:7]2[CH:8]=[CH:9][CH:10]=[C:11]([CH:12]3[CH2:17][CH2:16][N:15]([CH2:18][CH2:19][C@H:20]4[CH2:21][CH2:22][C@H:23]([NH:26][C:37](=[O:38])[C:36]5[CH:40]=[CH:41][C:33]([N:27]6[CH2:28][CH2:29][O:30][CH2:31][CH2:32]6)=[N:34][CH:35]=5)[CH2:24][CH2:25]4)[CH2:14][CH2:13]3)[C:6]=2[CH2:5][CH2:4]1Komponenten
3
Versuchsvorschrift
The title compound, off-white solid (100 mg, 78%), MS (ISP) m/z=519.4 [(M+H)+], mp 228° C., was prepared in accordance with the general method of example 1 from trans-4-{2-[4-(2,3-dihydro-benzofuran-4-yl)-piperidin-1-yl]-ethyl}-cyclohexylamine dihydrochloride (intermediate B) (100 mg, 0.25 mmol) and 6-morpholin-4-yl-nicotinic acid.
Quellen und Nachweise
- ORD-Eintrag
- ord-fdcdf188ae3c4793a83eb4cf5182cb62
- Quelldatensatz
- uspto-grants-2014_11